We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-9.55%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$541M
AUM Growth
+$81.3M
Cap. Flow
+$124M
Cap. Flow %
23%
Top 10 Hldgs %
62%
Holding
53
New
14
Increased
8
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$22.3M
2
XENT
Intersect ENT, Inc
XENT
+$14.2M
3
VRAY
ViewRay, Inc.
VRAY
+$12.6M
4
WMGI
Wright Medical Group Inc
WMGI
+$11.7M
5
ABBV icon
AbbVie
ABBV
+$10.6M

Top Sells

Rank Stock Value
1
PETX
Aratana Therapeutics, Inc.
PETX
+$37.5M
2
NVRO
NEVRO CORP.
NVRO
+$25.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$10.3M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$10M
5
ZGNX
Zogenix, Inc.
ZGNX
+$9.53M

Sector Composition

Rank Sector Weight
1 Healthcare 53.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGL icon
26
Sol-Gel Technologies
SLGL
$272M
$5.06M 0.94%
56,330
-16,680
-23% -$1.5M
ALKS icon
27
Alkermes
ALKS
$8.79B
$4.86M 0.9%
+249,000
New +$5.42M
XGN icon
28
Exagen
XGN
$106M
$4.82M 0.89%
+311,284
New +$5.02M
ICUI icon
29
ICU Medical
ICUI
$3.94B
$4.79M 0.89%
+30,000
New +$5.97M
QTNT
30
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.77M 0.88%
15,336
-658
-4% -$254K
CPRX
31
DELISTED
Catalyst Pharmaceutical
CPRX
$4.67M 0.86%
880,303
-1,884,767
-68% -$10M
ATRS
32
DELISTED
Antares Pharma, Inc.
ATRS
$4.47M 0.83%
1,336,700
-407,447
-23% -$1.34M
SIBN icon
33
SI-BONE Inc
SIBN
$771M
$3.95M 0.73%
223,291
-89,607
-29% -$1.72M
DERM
34
DELISTED
Dermira, Inc.
DERM
$3.7M 0.68%
+579,600
New +$4.84M
VCEL icon
35
Vericel Corp
VCEL
$2.38B
$3.59M 0.66%
237,050
-21,100
-8% -$369K
GWPH
36
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.45M 0.64%
+30,000
New +$4.55M
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$2.39M 0.44%
110,800
+36,014
+48% +$956K
ADMA icon
38
ADMA Biologics
ADMA
$2.02B
$2.25M 0.42%
505,900
-241,600
-32% -$1.01M
HRTX icon
39
CALL
Heron Therapeutics
HRTX
$89.1M
$1.85M 0.34%
100,000
– –
HRTX icon
40
Heron Therapeutics
HRTX
$89.1M
$1.82M 0.34%
98,237
-559,761
-85% -$10.3M
ACRS icon
41
Aclaris Therapeutics
ACRS
$793M
$1.75M 0.32%
+1,620,000
New +$2.3M
LJPC
42
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.6M 0.3%
181,844
-709,916
-80% -$6.71M
AMAG
43
DELISTED
AMAG Pharmaceuticals
AMAG
$1.16M 0.21%
+100,000
New +$1.05M
PTN
44
Palatin Technologies
PTN
$16.2M
$952K 0.18%
+838
New +$984K
DXCM icon
45
DexCom
DXCM
$29.6B
– –
-253,200
Closed -$9.48M
INCY icon
46
Incyte
INCY
$23.4B
– –
-66,600
Closed -$5.66M
MTNB icon
47
Matinas BioPharma
MTNB
$2.2M
– –
-15,334
Closed -$657K
MYGN icon
48
Myriad Genetics
MYGN
$584M
– –
-123,785
Closed -$3.44M
OPTN
49
DELISTED
OptiNose
OPTN
– –
-39,727
Closed -$4.22M
TVTX icon
50
CALL
Travere Therapeutics
TVTX
$5.27B
– –
-150,000
Closed -$3.01M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Broadfin Capital held 53 positions worth $541M, up 18% from $460M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Broadfin Capital deployed $124M of net new capital in Q3 2019, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Intersect ENT, Inc: 779,134 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was NEVRO CORP., an estimated $25.6M trimmed.

  • Broadfin Capital's largest Q3 2019 buy was Intersect ENT, Inc: 779,134 shares worth $13.3M.
  • Broadfin Capital added most to Amarin Corp in Q3 2019, an estimated $22.3M increase.
  • Broadfin Capital's biggest Q3 2019 reduction was NEVRO CORP., cutting an estimated $25.6M.
  • Broadfin Capital fully exited Aratana Therapeutics, Inc. in Q3 2019, selling an estimated $37.5M.
  • Broadfin Capital's ten largest holdings make up 62% of its $541M portfolio in Q3 2019.
  • Broadfin Capital opened 14 new positions and closed 9 in Q3 2019.
  • Broadfin Capital's portfolio value rose 18% quarter-over-quarter to $541M.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.